ATE167061T1 - Kreuzschützende salmonella impfstoffe - Google Patents

Kreuzschützende salmonella impfstoffe

Info

Publication number
ATE167061T1
ATE167061T1 AT90917076T AT90917076T ATE167061T1 AT E167061 T1 ATE167061 T1 AT E167061T1 AT 90917076 T AT90917076 T AT 90917076T AT 90917076 T AT90917076 T AT 90917076T AT E167061 T1 ATE167061 T1 AT E167061T1
Authority
AT
Austria
Prior art keywords
mutation
vaccines
salmonella
gene
possess
Prior art date
Application number
AT90917076T
Other languages
English (en)
Inventor
Roy Curtiss Iii
Maryann Munson
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE167061T1 publication Critical patent/ATE167061T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT90917076T 1989-11-03 1990-11-02 Kreuzschützende salmonella impfstoffe ATE167061T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43159789A 1989-11-03 1989-11-03

Publications (1)

Publication Number Publication Date
ATE167061T1 true ATE167061T1 (de) 1998-06-15

Family

ID=23712646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90917076T ATE167061T1 (de) 1989-11-03 1990-11-02 Kreuzschützende salmonella impfstoffe

Country Status (7)

Country Link
EP (1) EP0500699B1 (de)
JP (1) JPH05504331A (de)
AT (1) ATE167061T1 (de)
AU (1) AU6737190A (de)
CA (1) CA2072633A1 (de)
DE (1) DE69032408T2 (de)
WO (1) WO1991006317A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322092T2 (de) * 1992-09-04 1999-07-15 Univ Saskatchewan Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
CA2161405A1 (en) * 1993-04-26 1994-11-10 James L. Doran Methods and compositions for detection of salmonella
DE4333742A1 (de) * 1993-10-04 1995-04-06 Klaus Prof Dr Linde Lebendimpfstoff mit erhöhter Stabilität
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
NZ503376A (en) 1997-09-10 2002-10-25 Vion Pharmaceuticals Inc Genetically modified Salmonella sp having a modified msbB gene useful for treating tumours
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US6605285B2 (en) 2000-03-29 2003-08-12 G.B. Pant University Of Agriculture & Technology Vaccine for protection of poultry against salmonellosis and a process for preparing the same
EP1499191B1 (de) * 2002-04-15 2012-05-09 Washington University in St. Louis Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
EP2150616A4 (de) 2007-05-10 2011-07-27 Univ Arizona Geregelte antigensynthese und/oder geregelte attenuation zur verbesserung der impfstoff immunogenität und/oder -sicherheit
US9040059B2 (en) 2007-10-05 2015-05-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting a protective immune response against C. perfringens
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
EP2526185A4 (de) 2010-01-22 2013-07-24 Univ Arizona Bakterium mit einer regulierten rfah-nukleinsäure
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
BRPI1003750A2 (pt) 2010-07-22 2012-04-10 Univ Sao Paulo microrganismos recombinantes, métodos de preparação de linhagens vacinais, antìgenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN112175928B (zh) * 2020-10-13 2022-09-13 华中农业大学 一种源于沙门氏菌噬菌体基因编码的蛋白在作为革兰氏阴性菌裂解酶中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249449A1 (de) * 1986-06-11 1987-12-16 Enterovax Research Pty. Ltd. Bakterieller Stamm für lebende Impfstoffe
AU645489B2 (en) * 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms

Also Published As

Publication number Publication date
DE69032408T2 (de) 1998-10-08
JPH05504331A (ja) 1993-07-08
WO1991006317A1 (en) 1991-05-16
EP0500699B1 (de) 1998-06-10
CA2072633A1 (en) 1991-05-04
DE69032408D1 (de) 1998-07-16
AU6737190A (en) 1991-05-31
EP0500699A1 (de) 1992-09-02
EP0500699A4 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
ATE167061T1 (de) Kreuzschützende salmonella impfstoffe
Udhayakumar et al. Protective immunity induced by outer membrane proteins of Salmonella typhimurium in mice
Munson et al. Purification and comparison of outer membrane protein P2 from Haemophilus influenzae type b isolates.
EP0692031A4 (de) Heterologe antigene in stämmen zur impfung mit lebendzellen
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
PT88329A (pt) Bacterias nao virulentas contra infeccoes estreptococicas
HUT65496A (en) Live vaccines
ATE242319T1 (de) Deletionsmutanten als impfstoffe gegen cholera
DZ634A1 (fr) Mutants de vibrio cholerale non-toxinogènes.
Ortiz et al. Immunoblot detection of class-specific humoral immune response to outer membrane proteins isolated from Salmonella typhi in humans with typhoid fever
DK0512260T3 (da) Stabile purA-vektorer samt deres anvendelse
Nilsson et al. Two‐dimensional electrophoretic and immunoblot analysis of cell surface proteins of spiral‐shaped and coccoid forms of Helicobacter pylori
Thornton et al. Surface-disorganized, attenuated mutants of Aeromonas salmonicida as furunculosis live vaccines
Confer et al. Serum antibody responses of cattle to iron-regulated outer membrane proteins of Pasteurella haemolytica A1
SE9003198D0 (sv) Fish vaccine comprising a virulent, invasive bacterium
Jayappa et al. Role of Escherichia coli type 1 pilus in colonization of porcine ileum and its protective nature as a vaccine antigen in controlling colibacillosis
Guirguis et al. Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies.
Chatfield et al. Identification of the major antigens of Treponema hyodysenteriae and comparison with those of Treponema innocens
MY105080A (en) Heat-labile toxin b subunit fusion proteins.
Mintz et al. Electrophoretic and serological characterization of the lipopolysaccharide produced by Neisseria gonorrhoeae
Montie et al. Isolation and characterization of flagellar preparations from Pseudomonas species
Lachmann et al. Solubilization and characterization of surface antigenic components of Erysipelothrix rhusiopathiae T28
AU601415B2 (en) A process for the purification, solubilization and/or detoxification of protein antigens of bacteria of the bordetella genus using a carbonate buffer and an acellular anti-whooping cough vaccine
Barton et al. Further characterization of Renibacterium salmoninarum extracellular products
AU558008B2 (en) Ozone inactivated organisms as vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties